GenEdit: Sarepta Bets On GenEdit's Nanoparticles' In $57M Gene Editing Partnership

Sarepta Therapeutics Inc (NASDAQ: SRPT) will pay GenEdit up to $57 million in the near term for access to the biotech's non-viral delivery platform for gene-editing therapies. Sarepta will combine its gene-editing technology with GenEdit's NanoGalaxy platform to target up to four neuromuscular indications selected ...Full story available on Benzinga.com